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Abstract : Arteriovenous malformations (AVMs) are hemorrhagic vascular diseases in which arteries and veins 
are directly connected with no capillary bed between the two. We herein introduce the results of basic research 
of this disease and surgical techniques based on our data and experiences. The results obtained from our re-
search show that cell death- and inflammation-related molecules changed or became activated compared with 
control specimens. These findings indicate that chronic inflammation occurs in and around the nidus of AVMs. 
Various molecules are involved in the mechanisms of cell death and angiogenesis during this process. Confirma-
tion of blood flow in the nidus is very important to avoid hemorrhagic complications during surgical removal of 
the nidus. The risk of hemorrhage increases when the blood flow in the nidus is not reduced. We reported the 
advantages of serial indocyanine green videoangiography, which is used to assess the blood flow during AVM 
nidus removal. Since publication of the ARUBA trial and Scottish Audit, treatments with high morbidity have 
not been allowed. It is especially important for neurosurgeons to treat low Spetzler–Martin grade AVMs with low 
morbidity. J. Med. Invest. 67 : 222-228, August, 2020
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INTRODUCTION
 
Arteriovenous malformations (AVMs) are hemorrhagic vascu-
lar diseases in which arteries and veins are directly connected 
with no capillary bed between the two. Their origin is unknown, 
and they may cause intracerebral hemorrhage in younger pa-
tients. We herein introduce the results of basic research of 
this disease and surgical techniques based on our data and 
experiences. 
BASIC RESEARCH OF AVMS
Molecular and histological studies of human brain AVM 
specimens shows that the levels of angiogenic factors and in-
flammatory cytokines are higher in AVMs than those in normal 
brain. Brain AVMs are also infiltrated with inflammatory cells. 
However, the pathogenesis of brain AVMs is not completely 
clarified (1). Abnormal expression patterns of inflammatory 
mediators and cytokines, as well as an influx of inflammatory 
cells in AVMs, have been observed by a lot of investigators(2-6). 
Inflammatory markers are overexpressed in AVMs, including 
myeloperoxidase (MPO) and IL-6, both of which highly correlate 
with matrix MMP-9 expression. Remodeling of the vascular 
network in AVMs is facilitated by a number of proteases that 
can enlarge the vascular elements in the nidus. This remodeling 
is partially mediated through VEGF activity and modulated 
by proangiogenic signals such as MMP expression. MMP-9 is 
expressed at significantly higher levels in bAVMs than in control 
tissue (3,7). MMP-9 expression and activity during inflamma-
tion are stimulated by the cytokines IL-1β, and IL-6.
The main histopathological features of AVMs are venous ec-
tasia, microvessel proliferation, inflammatory cell infiltration, 
and endothelial thickening (Figure 1) (8). Among these char-
acteristics, endothelial thickening is more common in patients 
of advanced age, patients with a compact nidus, male patients, 
patients with Spetzler–Martin grade I or II AVMs, and patients 
with higher flow than in any other patients, according to our 
previous reports. In addition, venous ectasia is more common 
in patients of advanced age (8). Based on these characteristics, 
AVMs are not only vascular anomalies but are also dynami-
cally changing and active vascular lesions. We investigated the 
changes in vascular walls in the nidus and perinidal neurons 
of AVMs mainly by molecular immunohistochemical methods. 
First, we reported that apoptotic cells exist in the vascular walls 
of the nidus and perinidal areas (9). Proliferating cell nuclear 
antigen-positive cells possessing proliferative activity were locat-
ed in the walls of the nidus. In addition, these cells were positive 
for phosphorylated extracellular signal-regulated kinase (ERK), 
which is a mitogen-activated protein kinase (10). Phosphorylated 
ERK reportedly induces cell proliferation in many cell types. 
These observations indicate that many biological events occur in 
and around AVMs. Apoptosis of the neurons in perinidal areas 
occurs through caspase-8, which triggers neuronal apoptosis 
(11). In the vascular walls of the nidus and infiltrating cells 
around the nidus, transcription factors, including nuclear factor 
kappa B, Signal transduction and activator of transcription 
(STAT)3, and STAT1, are also activated (Figure 2) (5,12). These 
factors induce cell death and angiogenesis. In younger patients 
with early regrowth of the nidus, increased expression of CD105 
and phosphorylated ERK can induce angiogenesis (13). We also 
performed DNA array analysis using AVM specimens (14). 
Smooth muscle cells (SMCs) in the vascular walls have been 
reported to be involved in the remodeling process in AVMs. SMC 
dedifferentiation from a contractile to a synthetic phenotype 
occurs in brain AVMs, particularly in arterialized veins, which 
is characterized by the expression of smooth muscle myosin 
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heavy chain (Figure 3). The results obtained from this study 
showed that cell death- and inflammation-related genes changed 
compared with control specimens. These findings indicate that 
chronic inflammation occurs in and around the nidus of AVMs. 
Various molecules are involved in the mechanisms of cell death 
and angiogenesis during this process (Figure 4). 
A recent topic in basic research of AVMs is the presence of 
KRAS mutations in the endothelial cells of the nidus (15). We 
also reported KRAS mutations using Japanese samples (16). 
These observations also indicate that AVMs are not only con-
genital vascular malformations but also dynamically changing 
lesions.
Figure 1.　Hematoxylin-eosin staining of human brain AVM tissues. A. Neuronal death with various degrees of nuclear 
degeneration (arrows) at perinidal cortical tissues with accompanying moderate degree of gliosis. B. Increased intimal thickness 
at some regions of the venous wall (arrow). C. Severe venous enlargement. D. Infiltrating cells surrounding the vessels (arrows). 
E. Microvessel accumulation (arrows) with profound infiltrating cells at the enlarged and hyperplastic vein. F. Loss of neuronal 
structure at the cortical tissue with profound degree of reactive gliosis and neuronal death (arrows).
Figure 2.　Activation of STAT3 in the endothelial and perivascular 
infiltrating inflammatory cells of the AVM specimens (cytoplasmic 
and nuclear immunoreactivity).
A. Nuclear immunoreactivity for phospho-STAT3 Ser727 in the 
intima (arrows). B. No immunoreactivity for STAT3 in the control 
areas in a highly magnified image. C. Nuclear immunoreactivity for 
phospho-STAT3 Ser727 in the perivascular area (arrows). D. Nuclear 
immunoreactivity for phospho-STAT3 Tyr705 in the intima (arrows) 
(from Aziz et al., World Neurosurg 78(5) : 487-97, 2012).
Figure 3.　Photomicrographs of SMemb-positive vessels in human 
brain AVMs. A. SMemb expression at both vein and artery sites. B. 
Positive SMemb cells that were distributed along the tunica media 
through the intimal layer of the vein; furthermore, the positive cells 
had rounded morphology, presumably resembling the synthetic 
phenotype of VSMCs. C. SMemb-positive cells were spread out in the 
tunica media of the artery  (arrows). D. SMemb-positive cells at the 
intimal layer of veins  (arrows).
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SURGICAL TECHNIQUES OF AVMS
Base on the history of neurosurgery, one of the most famous 
modern neurosurgeons, Walter E. Dandy  termed AVMs as 
“arteriovenous aneurysms” and reported high morbidity and 
mortality after surgical treatment (17). More than 90 years since 
Dandy’s report, AVM is still difficult to be treated without mor-
bidity. Recently, two important reports were published about the 
treatment of AVMs. The surgical strategy for unruptured AVMs 
changed after publication of these two reports, the ARUBA trial 
and Scottish Audit (18,19). Furthermore, a novel scientific state-
ment from the AHA/ASA was published in 2017 (20). This state-
ment described the treatment of unruptured AVMs. Two clinical 
trials (ARUBA and the Scottish Audit) support more conser-
vative management of unruptured AVMs. However, two major 
limitations weaken the described management strategy. These 
clinical studies had short follow-up periods and included small 
numbers of juvenile patients. The surgical morbidity rate was 
higher than expected. Among patients with ruptured AVMs, 
small and superficial AVMs can be removed during emergency 
surgery ; however, emergency removal is associated with a risk 
of increased morbidity and mortality. Deep-seated AVMs should be 
treated 2 to 6 weeks after hemorrhage. In patients with Spetzler–
Martin high-grade AVMs, worsen neurological deficit was con-
sidered even in the cases of patients with neurological symptoms. 
Based on these statements, unruptured AVMs should be treated 
after consideration of the surgical risk, treatment modality, and 
life expectancy. In patients with ruptured AVMs, treatment op-
tions and modalities should be determined after careful consid-
eration of the surgical risks and benefits (20). We emphasize that 
safe surgical treatment and low morbidity are most important, 
especially in patients with unruptured AVMs.
The concept of direct microsurgery for AVMs involves dividing 
and removing easily accessed hemorrhagic vascular lesions from 
the brain tissue using the gliotic tissue, in which neurons are 
degenerating and decreasing in number (21,22,23). The use of 
non-stick bipolar forceps that do not stick to burned brain tissue 
and assessment of blood flow in the nidus during surgical remov-
al are important in this procedure (23,24). The steps of AVM 
nidus removal are as follows : (i) confirmation of the nidus, (ii) 
dissection of the arachnoid around the nidus, (iii) confirmation of 
the locations of feeders and drainers, (iv) clipping or coagulation 
of the feeders, (v) confirmation of blood flow in the nidus, (vi) 
subpial dissection of the nidus, (vii) nidus dissection, (viii) coag-
ulation and cutting of the drainers, and (ix) removal of the nidus 
(Figure 5) (22,23). Among these steps, confirmation of blood flow 
Figure 4.　Biological function of various molecules in and around 
the nidus of brain AVMs.
Figure 5.　Steps of microsurgical dissection for brain AVMs using ICG videoangiography. A. AVM nidus. B. 
Arachnoid dissection. C. Feeder and drainer confirmation. D. Feeder clipping. E. Confirmation of nidus flow by ICG 
videoangiography. Color map represents the flow speed in the nidus assessed by FLOW800 software based on fluorescent 
image evoked by Near infrared ray under operative microscope. Red is fast flow and blue is slow flow. F. Subpial 
dissection. G. Nidus dissection. H. Drainer coagulation. I. Nidus removal
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in the nidus is very important for avoiding hemorrhagic compli-
cations. The risk of hemorrhage increases when the blood flow 
in the nidus is not reduced. We first reported the advantages of 
serial indocyanine green (ICG) videoangiography, which is used 
to assess the blood flow during AVM nidus removal. In 2007, 
we introduced this technique after receiving approval from the 
ethics committee of Kyoto University Graduate School of Medi-
cine. In 2007, we also reported its usefulness in assessment of a 
residual nidus in children with AVM. In 2010, we reported the 
advantages and efficacy of this technique in the surgical treat-
ment of AVMs (24). We now employ this technique in our hybrid 
operation room using simultaneous cerebral angiography at 
Kyoto University. At Tokushima University, we also employ this 
method in the hybrid operation room and use it for intra-arterial 
administration of ICG. This method allows surgeons to achieve 
a clearer and sharper image of ICG (Figure 6). Furthermore, 
we reported the usefulness of three-dimensional simulation in 
the surgical treatment of AVMs (23,25). Using Amira or Vin-
cent software, an operative view can be obtained before surgery 
with a combination of magnetic resonance imaging, cerebral 
angiography, and computed tomography. Three-dimensional 
simulation reveals the location of the deep-seated feeders and 
the extent of the nidus, enabling surgeons to perform safe direct 
surgical treatment of AVMs (Figure 7). In addition, the combina-
tion of magnetic resonance imaging and tractography allows vi-
sualization of the corticospinal tract and confirms the location of 
the tract that the surgeon should not injure. Three-dimensional 
simulation is effective for avoiding postoperative complications.
 
CASE ILLUSTRATIONS
Case 1. A 43-year-old woman with an unruptured frontal 
Spetzler–Martin grade II AVM underwent surgical treatment 
after coil embolization of the feeders. Transarterial ICG videoan-
giography showed blood flow from the middle cerebral artery and 
vertebral artery on Flow 800 software (Figures 6 and 8).
Case 2. A 13-year-old boy with a ruptured occipital Spetzler–
Martin grade III AVM underwent transarterial ICG videoangi-
ography, which showed blood flow in the drainer (Figure 9).
REAL-WORLD SURGICAL TREATMENT OF AVMS
AVM patients are referred to Kyoto University hospital not 
only from Kyoto prefecture but also from Osaka, Shiga, and 
other prefectures. Both surgically treated patients and conser-
vatively managed patients are admitted to the hospital. From 
January 2008 to October 2017, 102 patients were admitted to the 
hospital. Among them, 62 patients were surgically treated ; 91% 
of patients with Spetzler–Martin grade I and II AVMs and 46% 
of patients with Spetzler–Martin grade III and IV AVMs were 
surgically treated. Among those with grade II AVMs, non-hem-
orrhagic cases tended to be treated by stereotactic radiosurgery. 
More recently, the proportion of patients treated by direct sur-
gery has decreased and the proportion treated by irradiation 
has increased. Patients are referred to Tokushima University 
Hospital from the entirety of Tokushima prefecture and parts of 
Kagawa, Ehime, and Kochi prefectures. Most admitted patients 
are surgically treated. Tokushima University Hospital has a 
stroke care unit. About 300 patients per year are admitted to 
the hospital. Among them, about 60 patients have hemorrhagic 
Figure 6.　Transarterial ICG videoangiography in Case 1. A. ICG 
videoangiography from the catheter placed in the internal carotid 
artery discloses blood supply from feeders from the middle cerebral 
artery (see circle and arrow). B. ICG videoangiography from the 
catheter placed in the vertebral artery discloses blood supply from 
feeders from the posterior cerebral artery (see circle and arrow). (Rt. 
CAG: right carotid angiogram, Rt.VAG: right vertebral angiogram). 
Color map represents the flow speed in the nidus assessed by 
FLOW800 software based on fluorescent image evoked by Near 
infrared ray under operative microscope. Red is fast flow and blue is 
slow flow. C. Intraoperative view after total dissection of the nidus of 
AVM.
Figure 7.　3D simulation image. Red: artery, green: nidus, blue: 
vein. A. The location and relationship between the nidus and vessels 
are indicated. B. The nidus is buried in the interhemispheric surface 
of the brain.
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Figure 8.　Case 1. A. Right internal cerebral angiogram (lateral view). B. Right internal cerebral angiogram (AP 
view). C. MRI T2 weighed image; AVM is located in the right frontal lobe. D and E. intraoperative view.
Figure 9.　Case 2. A. CT. B. Right vertebral angiogram (AP view). C. Right vertebral angiogram (lateral view). 
AVM is located in the left occipital lobe. D. ICG videoangiography from the catheter placed in vertebral artery 
discloses blood in the drainer (see arrow). White signal means fluorescent image evoked by Near infrared ray 
under operative microscope. The density and speed of white signal means blood volume and blood flow. E. 
Intraoperative view.
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disease. From January 2008 to March 2020, 41 patients with 
AVMs were surgically treated ; 30 had hemorrhagic disease 
and 11 had non-hemorrhagic disease. Twenty-nine patients had 
Spetzler–Martin grade I or II AVMs (26). 
FUTURE PERSPECTIVE
Since publication of the ARUBA trial and Scottish Audit, 
treatment with high morbidity has not been allowed. It is im-
portant for us to achieve surgical treatment of Spetzler–Martin 
grade I and II AVMs with low morbidity. For Spetzler–Martin 
high-grade AVMs, it is also important to select which cases can 
be treated with low morbidity. Novel treatments are needed for 
patients with a poor prognosis or high morbidity. Both our basic 
research and recent studies on genetic mutations in the endothe-
lium of the nidus show that AVMs are not only congenital vascu-
lar anomalies but also dynamically changing lesions.
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